Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,512.38 -3.89 -0.03%
TOPIX 1,171.40 -1.97 -0.17%
HANG SENG 22,760.24 64.23 0.28%

Illumina Comments on a Ruling in its Patent Litigation Against Complete Genomics, Inc.



  Illumina Comments on a Ruling in its Patent Litigation Against Complete
  Genomics, Inc.

Business Wire

SAN DIEGO -- October 18, 2012

Illumina, Inc. (NASDAQ: ILMN) announced today that Magistrate Judge Elizabeth
D. LaPorte of the U.S. District Court for the Northern District of California
granted a motion for summary judgment of invalidity filed by Complete
Genomics, Inc. against certain claims of Illumina’s U.S. Patent No. 6,306,597.
Over Illumina’s objections, the Court found that these claims were not novel
over the prior art. The summary judgment ruling did not address a number of
additional patent claims being asserted by Illumina against Complete Genomics
that were not the subject of the validity motion.

Jay Flatley, Illumina’s President and Chief Executive Officer, stated, “We
strongly disagree that any of the claims of our patent are invalid, and we
intend to appeal the Court’s ruling. We believe that this patent covers
important and novel inventions that Complete Genomics has misappropriated.”
Illumina also continues to vigorously protect its rights under a second patent
that Illumina more recently asserted against Complete Genomics in the U.S.
District Court for the Southern District of California.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements are detailed in our
filings with the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this
release.

Contact:

Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple
858-882-6822
pr@illumina.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement